The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 25, 2023

Filed:

May. 20, 2015
Applicant:

Lts Lohmann Therapie-systeme Ag, Andemach, DE;

Inventors:

Marco Emgenbroich, Rheinbach, DE;

Elke Klein, Bad Neuenahr-Ahrweiler, DE;

Heike Kluth, Ochtendung, DE;

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/70 (2006.01); A61K 31/381 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/7069 (2013.01); A61K 9/0014 (2013.01); A61K 9/7053 (2013.01); A61K 9/7061 (2013.01); A61K 9/7084 (2013.01); A61K 9/7092 (2013.01); A61K 31/381 (2013.01);
Abstract

A transdermal therapeutic system containing rotigotine base in a self-adhesive layer structure. The system includes a backing layer, and a rotigotine-containing biphasic layer. The biphasic layer has an outer phase having a composition including 75% to 100% of a polymer or a polymer mixture, and an inner phase that forms dispersed deposits in the outer phase. The inner phase includes rotigotine base and a polymer mixture of at least two hydrophilic polymers. The hydrophilic polymers are selected from the group of polyvinylpyrrolidones having a K-Value of at least 80, polyvinylpyrrolidones having a K-Value of less than 80, copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, copolymers of vinylpyrrolidone and vinylacetate, copolymers of ethylene and vinylacetate, polyethylene glycols, polypropylene glycols, acrylic polymers, and modified celluloses. The polymer mixture in the inner phase is present in an amount sufficient so that it forms a solid solution with the rotigotine base.


Find Patent Forward Citations

Loading…